Epalrestat , an Aldose Reductase Inhibitor , Reduces the Levels of N ε-( Carboxymethyl ) lysine Protein Adducts and Their Precursors in Erythrocytes From Diabetic Patients

OBJECTIVE To clarify the role of the polyol pathway in the intracellular formation of advanced glycation end products in human tissues, we examined the effects of epalrestat, an aldose reductase inhibitor, on the level of Nepsilon-(carboxymethyl)lysine (CML) along with 3-deoxyglucosone (3-DG) and triosephosphates in erythrocytes from diabetic patients. Plasma thiobarbituric acid-reactive substances (TBARS) were also determined as indicators of oxidative stress. RESEARCH DESIGN AND METHODS Blood samples were collected from 12 nondiabetic volunteers, 38 untreated type 2 diabetic patients, and 16 type 2 diabetic patients who had been treated with 150 mg epalrestat/day. Blood samples were also collected from 14 of the untreated type 2 diabetic patients before and after the administration of epalrestat for 2 months. The amount of erythrocyte CML was determined by a competitive enzyme-linked immunosorbent assay, and 3-DG was measured by high-performance liquid chromatography RESULTS In diabetic patients not treated with epalrestat, the erythrocyte CML level was significantly elevated above levels seen in nondiabetic individuals (49.9 +/- 5.0 vs. 31.0 +/- 5.2 U/g protein, P < 0.05) and was significantly lower in patients receiving epalrestat (33.1 +/- 3.8 U/g protein, P < 0.05). Similar results were observed with 3-DG. The treatment of patients with epalrestat for 2 months significantly lowered the level of erythrocyte CML (46.2 +/- 5.6 at baseline vs. 34.4 +/- 5.0 U/g protein, P < 0.01) along with erythrocyte 3-DG (P < 0.05), triosephosphates (P < 0.05), fructose (P < 0.05), sorbitol (P < 0.05), and plasma TBARS (P < 0.05) without changes in plasma glucose and HbA(1c) levels. A positive correlation was evident between the erythrocyte CML and sorbitol (r = 0.49, P < 0.01) or fructose (r = 0.40, P < 0.05) levels in diabetic patients. CONCLUSIONS The results indicate that epalrestat administration lowers CML and associated variables and that polyol metabolites are correlated with CML in the erythrocytes of diabetic patients. The observed results suggest that aldose reductase activity may play a substantial role in the intracellular formation of CML in the mediation of reactive intermediate metabolites and oxidative stress.

[1]  T. Lyons,et al.  Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.

[2]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[3]  J. Baynes,et al.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. , 1995, Biochemistry.

[4]  V. Monnier,et al.  Suppression of Pentosidine Formation in Galactosemic Rat Lens by an Inhibitor of Aldose Reductase , 1994, Diabetes.

[5]  C. Yabe-Nishimura,et al.  Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication , 1998 .

[6]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Lyons,et al.  Toxicity of Mildly Modified Low-Density Lipoproteins to Cultured Retinal Capillary Endothelial Cells and Pericytes , 1994, Diabetes.

[8]  M. Cotter,et al.  Metabolic and Vascular Factors in the Pathogenesis of Diabetic Neuropathy , 1997, Diabetes.

[9]  M. Kasuga,et al.  Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. , 1994, The Journal of biological chemistry.

[10]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Hammes,et al.  Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Ne-(carboxymethyl) lysine independently of glycohaemoglobin concentrations , 1999, Diabetologia.

[12]  V. Monnier,et al.  Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.

[13]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[14]  N. Hotta,et al.  Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients. , 1995, Life sciences.

[15]  A. Oronsky,et al.  Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats. , 1988, The Journal of clinical investigation.

[16]  Y. Morino,et al.  Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. , 1991, The Journal of biological chemistry.

[17]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[18]  N Taniguchi,et al.  Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. , 1998, Atherosclerosis.

[19]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[20]  D. V. Vander Jagt,et al.  Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. , 1992, The Journal of biological chemistry.

[21]  P. Raskin,et al.  Association of Erythrocyte Aldose Reductase Activity with Diabetic Complications in Type 1 Diabetes Mellitus , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[22]  N. Hotta,et al.  Effects of Glycemic Control on Plasma 3-Deoxyglucosone Levels in NIDDM Patients , 1997, Diabetes Care.

[23]  J. Malone,et al.  Red Cell Sorbitol: An Indicator of Diabetic Control , 1980, Diabetes.

[24]  池田和義.  N[ε]-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced Glycation End Products of the Maillard Reaction(カルボキシメチルリジン付加体はメイラード反応後期生成物の主要エピトープある) , 1997 .

[25]  M. Brownlee,et al.  Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. , 1998, Diabetes.

[26]  Paul J Thornalley,et al.  The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. , 1993, European journal of biochemistry.

[27]  J. Nyengaard,et al.  Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. , 1995, Investigative ophthalmology & visual science.

[28]  Paul J Thornalley,et al.  The formation of methylglyoxal from triose phosphates , 1993 .

[29]  T. Brown,et al.  31P–Nuclear Magnetic Resonance Evidence of an Activated Hexose-Monophosphate Shunt in Hyperglycemic Rat Lenses In Vivo , 1995, Diabetes.

[30]  H. Kaneto,et al.  DNA cleavage induced by glycation of Cu,Zn-superoxide dismutase. , 1994, The Biochemical journal.

[31]  V. Monnier,et al.  Tissue-Specific Effects of Aldose Reductase Inhibition on Fluorescence and Cross-Linking of Extracellular Matrix in Chronic Galactosemia: Relationship to Pentosidine Cross-Links , 1991, Diabetes.

[32]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[33]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[34]  T. Slater,et al.  The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. General features of the systems used. , 1971, The Biochemical journal.

[35]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[36]  Paul J Thornalley,et al.  Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. , 1993, Biochemical pharmacology.

[37]  V. Monnier,et al.  Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. , 1991, The Journal of biological chemistry.

[38]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[39]  H. Sano,et al.  Hydroxyl Radical Mediates Nϵ-(Carboxymethyl)lysine Formation from Amadori Product , 1997 .

[40]  J. Baynes,et al.  N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.

[41]  P. Kador,et al.  Inhibition of aldehyde reductase by aldose reductase inhibitors. , 1990, Biochemical pharmacology.

[42]  N. Hotta,et al.  Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. , 1996, Biochemical and biophysical research communications.

[43]  Keiichiro Suzuki,et al.  Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. , 1996, The Biochemical journal.

[44]  N. Hotta.  New approaches for treatment in diabetes: aldose reductase inhibitors. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[45]  K. Sato,et al.  Monkey 3-deoxyglucosone reductase: tissue distribution and purification of three multiple forms of the kidney enzyme that are identical with dihydrodiol dehydrogenase, aldehyde reductase, and aldose reductase. , 1993, Archives of biochemistry and biophysics.

[46]  F. Oski,et al.  Metabolic alterations in the human erythrocyte produced by increases in glucose concentration. The role of the polyol pathway. , 1971, The Journal of clinical investigation.

[47]  T. Brown,et al.  Identification of fructose 3-phosphate in the lens of diabetic rats. , 1990, Science.

[48]  N. Taniguchi,et al.  Site-specific and random fragmentation of Cu,Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. , 1992, The Journal of biological chemistry.

[49]  T. Brown,et al.  Detection of fructose-3-phosphokinase activity in intact mammalian lenses by 31P NMR spectroscopy. , 1993, The Journal of biological chemistry.

[50]  M. Brownlee,et al.  Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.

[51]  N. Taniguchi,et al.  Increased glycated Cu,Zn-superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetis mellitus. , 1992, The Journal of clinical endocrinology and metabolism.

[52]  A. Cerami,et al.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications. , 1984, Annals of internal medicine.

[53]  J. Hothersall,et al.  Effect of Aldose Reductase Inhibitor (Sorbinil) on Integration of Polyol Pathway, Pentose Phosphate Pathway, and Glycolytic Route in Diabetic Rat Lens , 1986, Diabetes.